Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.49 |
| ▸ | SMO | Q99835 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3559852 | 0.94 | KDM4E (0.54) | KDM4ELMNAABL1MAPTSMN1; SMN2 | |
| SCHEMBL23207522 | 0.86 | KDM4E (0.62) | KDM4ELMNAABL1MAPTSMN1; SMN2 | |
| SCHEMBL16238574 | 0.84 | KDM4E (0.60) | KDM4ELMNAABL1MAPTSMN1; SMN2 | |
| SCHEMBL30582921 | 0.84 | KDM4E (0.60) | KDM4ELMNAABL1MAPTSMN1; SMN2 | |
| SCHEMBL1646635 | 0.83 | KDM4E (0.57) | KDM4ELMNAABL1MAPTSMN1; SMN2 | |
| SCHEMBL17035908 | 0.81 | ADRB1 (0.60) | KDM4ELMNAABL1MAPTSMN1; SMN2 | |
| SCHEMBL30101389 | 0.81 | ADRB1 (0.60) | KDM4ELMNAABL1MAPTSMN1; SMN2 | |
| SCHEMBL231823 | 0.81 | ADRB1 (0.60) | KDM4ELMNAABL1MAPTSMN1; SMN2 | |
| SCHEMBL29959269 | 0.81 | MAPT (0.62) | KDM4ELMNAABL1MAPTSMN1; SMN2 | |
| SCHEMBL8082196 | 0.81 | SMN1; SMN2 (0.62) | KDM4ELMNAABL1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190070149-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-03-07 | — | — | US | claimed |
| US-9328107-B2 | Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | claimed |
| US-20150232420-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | EVOTEC (UK) LTD. (GB) | 2015-08-20 | — | — | US | claimed |
| EP-2018371-B1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2015-03-04 | — | — | EP | claimed |
| US-20140235622-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | claimed |
| WO-2014047288-A2 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | DOMINGUEZ CELIA (US) | 2014-03-27 | — | — | WO | claimed |
| US-20120270861-A1 | Primary Amines And Derivatives Thereof As Modulators Of The 5-HT2A Serotonin Receptor Useful For The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. | 2012-10-25 | — | — | US | claimed |
| US-20090197935-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | US | claimed |
| EP-2018371-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2009-01-28 | — | — | EP | claimed |
| US-20080194545-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | TRIUS THERAPEUTICS (US) | 2008-08-14 | — | — | US | claimed |
| WO-2008098143-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE | TRIUS THERAPEUTICS (US) | 2008-08-14 | — | — | WO | claimed |
| WO-2007136703-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | claimed |
| US-10226459-B2 | Aza spiro alkane derivatives as inhibitors of metalloproteases | INCYTE HOLDINGS CORPORATION (US) | 2019-03-12 | — | — | US | disclosed |
| US-20190070149-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-03-07 | — | — | US | disclosed |
| US-20180153882-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | INCYTE CORPORATION | 2018-06-07 | — | — | US | disclosed |
| US-9987252-B2 | Primary amines and derivitves thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20080194545-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | TRIUS THERAPEUTICS (US) | 2008-08-14 | — | — | US | disclosed |
| EP-0958287-B2 | SULFAMIDE-METALLOPROTEASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007138355-A1 | PYRROLO[1,2-A]PYRAZIN-1(2H)-ONE AND PYRROLO[1,2-D][1,2,4]TRIAZIN-1(2H)-ONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-12-06 | — | — | WO | disclosed |
| EP-0958287-B1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2002-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194545-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | ABCB11, FPR1, C5 | KDM4E 4460/4885LMNA 3111/4885ABL1 857/4885 |
| US-20140235622-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR1A | KDM4E 2520/4885LMNA 2106/4885ABL1 229/4885 |
| US-20190070149-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR1A | KDM4E 2520/4885LMNA 2106/4885ABL1 229/4885 |
| US-10226459-B2 | Aza spiro alkane derivatives as inhibitors of metalloproteases | MMP9, MMP3, MMP12 | KDM4E 1268/4885LMNA 2622/4885ABL1 3117/4885 |
| US-20120270861-A1 | Primary Amines And Derivatives Thereof As Modulators Of The 5-HT2A Serotonin Receptor Useful For The Treatment Of Disorders Related Thereto | HTR5A, HTR2A, HTR1A | KDM4E 2520/4885LMNA 2106/4885ABL1 229/4885 |
| US-20090197935-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR1A | KDM4E 2574/4885LMNA 1736/4885ABL1 185/4885 |
| US-20150232420-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | HTT, TGM2, GRN | KDM4E 2371/4885LMNA 4158/4885ABL1 1883/4885 |
| US-20180153882-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | MMP9, MMP3, MMP12 | KDM4E 1268/4885LMNA 2622/4885ABL1 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.